2021

Families USA Federal Comment Letter on TennCare III

Families USA submitted this letter in response to CMS' request for comments on Tennessee's Section 1115 demonstration that was approved in the final days of the Trump Administration. Multiple eleme...

Virtual Roundtable: Taking Action to Lower Prescription Drug Costs

Virtual Roundtable: Taking Action to Lower Prescription Drug Costs [embed]https://youtu.be/0SOpQHIGvJ4[/embed] As Congress returns this month to finalize the $3.5 billion reconciliation package,...

What’s at Stake for America’s Families: Why Congress Must Go Big and Bold in Reconciliation to Improve Health and Health Care for Millions of People

Congress is working to pass a vitally important budget reconciliation bill that would significantly lower health care costs, narrow racial and ethnic disparities in health and health care, and ensure ...

What Children and Families Need in Budget Reconciliation: Policy Recommendations to Improve Health and Well-Being

As Congress works to develop a robust budget reconciliation package, now is the time to ensure the inclusion of legislation that advances health equity and improves the health of parents and their chi...

Over 75 organizations thank key senators for their leadership on prioritizing Medicare price negotiations

On August 19, 2021, Families USA led over 75 national, state, and community organizations in thanking five key Senators who courageously filed an amendment that declared strong support for including M...

Administrative Advocacy Toolkit: No Surprises Act and Hospital Price Transparency

As Congress continues to negotiate the inclusion of critical health provisions in the next recovery package, we must not lose sight of important regulations that the Biden Administration is working to...

Our Broken Drug Pricing and Patent System Diverts Resources Away from Innovation and into Mergers, Patent Gaming and Price Gouging

As Congress considers ways to reform drug pricing this year, it is, unsurprisingly, being met with heavy resistance from paid special interests, including pharmaceutical companies’ lawyers and lobby...